Pennsylvania is currently home to 3313 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Communication About Sexual Health in Gynecologic Cancer
NCT06904339
Recruiting
The goal of this clinical trial is to learn if an educational video and workbook can help gynecologic cancer patients talk to their cancer providers about sexual health concerns. The main questions it aims to answer are: 1. Do gynecologic cancer patients who take part in the educational program and get a resource booklet talk to their cancer clinicians more about sexual health concerns than patients who get a resource booklet alone? 2. Do gynecologic cancer patients who take part in the educat... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Gynecologic Cancers
Register for Updates
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD
NCT06883305
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
03/31/2025
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06647498
Recruiting
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Register for Updates
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
NCT06602258
Recruiting
The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 18 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
03/31/2025
Locations: Abington Neurological Associates Ltd, Abington, Pennsylvania
Conditions: Alzheimer's Disease
Register for Updates
BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S
NCT06540079
Recruiting
The purpose of the BIO-CONDUCT study is to demonstrate the safety and effectiveness of the BIOTRONIK Solia CSP S pacing lead when implanted in the left bundle branch area (LBBA). Safety will be assessed by evaluating serious adverse device effects that occur through 3 months post-implant. Efficacy will be assessed by evaluating implant success rate.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Cardiology Consultants of Philadelphia, Paoli, Pennsylvania
Conditions: Sinus Node Dysfunction, Bradycardia, Atrioventricular Block
Register for Updates
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)
NCT06534983
Recruiting
The main purpose of the study is to evaluate the efficacy of adjuvant treatment with autogene cevumeran plus nivolumab compared with nivolumab in participants with high risk MIUC. In this study participants will be enrolled in a safety run-in phase to receive autogene cevumeran + nivolumab. This phase will be conducted to monitor and ensure the safety of study participants. After all participants in the safety run-in have been enrolled to receive autogene cevumeran + nivolumab, further particip... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: AHN Cancer Institute ? Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Muscle Invasive Urothelial Carcinoma
Register for Updates
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220
Recruiting
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Site 43, Philadelphia, Pennsylvania
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06510374
Recruiting
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Ferring Investigational Site, Bala-Cynwyd, Pennsylvania
Conditions: Intermediate Risk Non-Muscle Invasive Bladder Cancer
Register for Updates
Registry for Stage 2 Type 1 Diabetes
NCT06481904
Recruiting
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D. The purpose of this study is to collect general... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/31/2025
Locations: Hospital of The University of Pennsylvania- Site Number : 8400021, Philadelphia, Pennsylvania
Conditions: Type 1 Diabetes
Register for Updates
Acellular Dermal Matrix Investigation in Breast Reconstruction
NCT06456554
Recruiting
Prospective, multi-center, dual-arm non-randomized clinical study in females undergoing a two-stage breast reconstruction using a pre-pectoral technique.
Gender:
FEMALE
Ages:
22 years and above
Trial Updated:
03/31/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Breast Reconstruction
Register for Updates
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT06435429
Recruiting
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Metastatic HER2-positive Breast Cancer
Register for Updates
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
NCT06423430
Recruiting
The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
03/31/2025
Locations: Pennsylvania Hospital, Philadelphia, Pennsylvania
Conditions: Treatment Resistant Depression
Register for Updates